InDex will receive $10M up front for the exclusive rights to commercialize cobitolimod in Japan & is eligible to receive development and sales milestones of ~$40M along with royalties based on its net sales for the product in Japan
InDex will be in charge of continuing to fund all development incorporating the completion of the P-III program (CONCLUDE) incl. a cohort of Japanese patients in (Induction Study 2) and a PK study before filing. Viatris will be responsible to fund all regulatory and commercialization expenses, as well as any additional Japanese-specific studies required in Japan
Cobitolimod, a TLR9 agonist is being evaluated in the P-III program (CONCLUDE) for mod. to sev. UC
Ref: PRNewswire | Image: Viatris
Related News:- Viatris and Sandoz Report Results of Hulio and Hyrimoz (biosimilar, adalimumab) for the Treatment of Inflammatory Bowel Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
